

Stereotactic Radiosurgery for Brain Metastases Secondary to Peripheral Neural Crest Tumors: A Single Institution Retrospective Experience

Open Access

Abstract

Published 03/05/2025

Copyright

© Copyright 2025

Kattaa et al. This is an open access abstract distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Distributed under

Creative Commons CC-BY 4.0

Ahed H. Kattaa¹, Amit Persad², David J. Park³, Yusuke S. Hori⁴, Sara Emrich², Louisa Ustrzynski², Armine Tayag², Xuejun Gu⁵, Elham Rahimy⁶, Steven D. Chang⁷

1. Department of Neurosurgery, University of Stanford School of Medicine, Stanford, USA 2. Neurosurgery, Stanford University School of Medicine, Stanford, USA 3. Neurosurgery, Stanford University School of Medicine, Palo Alto, USA 4. Neurosurgery, Stanford University School of Medicine, Palo Alto, USA 5. Radiation Oncology, Department of Radiation Oncology, Stanford University, Stanford, USA 6. Radiation Oncology, Stanford University School of Medicine, Palo Alto, USA 7. Department of Neurosurgery, Stanford University School of Medicine, Stanford, USA

Corresponding author: Ahed H. Kattaa, akattaa@stanford.edu

Categories: Medical Physics, Radiation Oncology

Keywords: brain metastases, peripheral neural crest tumor, stereotactic radiosurgery

How to cite this abstract

Kattaa A H, Persad A, Park D J, et al. (March 05, 2025) Stereotactic Radiosurgery for Brain Metastases Secondary to Peripheral Neural Crest Tumors: A Single Institution Retrospective Experience. Cureus 17(3): a1501

Abstract

Objectives:

Intracranial BM of peripheral neural crest tumors (PNCTs) are rare, and portend a poor prognosis. No standard treatment has been established to date, and only a few case reports describe the usage of stereotactic radiosurgery (SRS). This study aims to evaluate the efficacy of SRS for BM secondary to PNCTs. Additionally, a comparison between SRS and other treatment modalities has been conducted

Methods:

We retrospectively reviewed all patients diagnosed with BM from PNCTs between 2001 and 2024 at our institution. LTC was defined as a reduction/stable in tumor size, with no recurrence or hemorrhage as evidenced by radiological assessment.

Results:

Among the 8 patients (15 BM) identified, 3 with 6 BM underwent SRS, and 5 with 9 BM underwent other treatments (radiotherapy, craniotomy, both or none). Amongst the patients treated with SRS, the median age was 4.0 years (IQR: 1.8-4.0 years) at diagnosis and 100% were male. The median follow-up was 5.5 months (IQR: 2-7 months). Amongst the patients not treated with SRS, the mean age was 2.5 years (Std. deviation: 1.4 years) at diagnosis and 60% were female. The median follow-up was 28 months (IQR: 1- 85 months). The group treated with SRS had LTC rate of 100% with no complications and a survival rate of 33.3% at one year follow up. LTC rate in the group treated with other modalities was 55.6%, with a survival rate of 60% for a one year follow up. There was no significant difference in LTC and survival between groups ($p > 0.05$).

Conclusion(s):

SRS provides a LTC rate of 100% within one year of follow up for BM from PNCTs. We do suggest that there is similarity of outcomes between SRS and other treatment modalities. SRS may be an alternative to more invasive treatments such as craniotomy or conventional radiation in these patients.